Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (DE:5Y6)
MUNICH:5Y6
COMPASS Pathways (5Y6) Stock Price & Analysis
2 Followers
5Y6 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.84 - €11.70
Previous Close€7.2
Volume0.00
Average Volume (3M)172.00
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$143.21M
Total Debt (Recent Filing)$1.93M
Price to Earnings (P/E)N/A
Beta0.39
Next Earnings
May 09, 2024EPS Estimate
-€0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume172
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
€45.64Price Target Upside533.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
COMPASS Pathways News
Bulls Say, Bears Say
Bulls Say
Clinical ProgressCOMP360 is progressing in Phase 2 and 3 trials with data updates expected later in 2023 and 2024.
Market PotentialPsilocybin as a potential treatment for neuropsychiatry conditions has grown in recent years, indicating a wider interest in Compass's COMP360.
Regulatory AlignmentFDA's publication of guidance for psychedelic drug development and alignment with COMP360's development plan is encouraging for its path to market.
Bears Say
Clinical Trial ProgressThe COMP-005 study delay, attributed to complications in confirming TRD diagnosis, may negatively impact the company's research timeline.
Financial PerformanceOperating expenses significantly exceeded expectations due to unpredictable timing on an R&D credit, raising concerns over financial management.
Management StabilityResignations of George Goldsmith and Dr. Katya Malievskaya from their board seats could signal potential management instability.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
7.62% Other Institutional Investors
92.38% Public Companies and
Individual Investors
5Y6 FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €4.84 and its highest was €11.70 in the past 12 months.
What is COMPASS Pathways’s market cap?
Currently, no data Available
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 09, 2024 which is in 6 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Feb 29, 2024. The company reported -€0.495 earnings per share for the quarter, missing the consensus estimate of -€0.337 by -€0.158.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -€0.45.
How many shares outstanding does COMPASS Pathways have?
Currently, no data Available
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -€0.495 in its last earnings report, missing expectations of -€0.337. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Among the largest hedge funds holding COMPASS Pathways’s share is ARK Investment Management LLC. It holds COMPASS Pathways’s shares valued at 23M.
---
COMPASS Pathways Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€45.64 (533.83% Upside)
€45.64 (533.83% Upside)
Blogger Sentiment
Bullish
DE:5Y6 Sentiment 83%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.51%
12-Months-Change
Fundamentals
Return on Equity
-58.41%
Trailing 12-Months
Asset Growth
39.89%
Trailing 12-Months
Company Description
COMPASS Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
---
5Y6 Earnings Call
Q4 2024
0:00 / 0:00
---
5Y6 Stock 12 Months Forecast
Average Price Target
€45.64
▲(533.83% Upside)
Technical Analysis
COMPASS Pathways
―
Reviva Pharmaceuticals Holdings
―
Alkermes
―
ACADIA Pharmaceuticals
―
Axsome Therapeutics
―
Best Analysts Covering 5Y6
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-10.53%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -10.53% per trade.
---